Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2040 studies found for:    melanoma
Show Display Options
RSS Create an RSS feed from your search for:
melanoma
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
2 Completed
Has Results
Melanoma Perception and Health Literacy in People of Color
Condition: Melanoma
Interventions: Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
3 Active, not recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
4 Not yet recruiting Tracing Dissemination of Melanoma Cells in Healthy Tissues
Condition: Melanoma
Intervention: Procedure: Melanoma and peritumoral skin excision
5 Recruiting Prospective Melanoma Database
Condition: Melanoma
Intervention: Other: clinical biological data collection on melanoma
6 Active, not recruiting Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: 4-peptide and 12-peptide melanoma vaccines
7 Not yet recruiting Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Standard therapy or clinical trial;   Drug: Matched targeted therapy;   Drug: Trametinib and / or supportive care
8 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
9 Completed Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Condition: Melanoma
Interventions: Biological: melanoma GVAX;   Drug: Cyclophosphamide
10 Recruiting Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
Condition: Metastatic Melanoma
Intervention: Other: patients with metastatic melanoma
11 Recruiting Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib
12 Completed Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
13 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
14 Active, not recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
15 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
16 Completed Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
17 Recruiting MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Condition: Cutaneous Melanoma by AJCC V7 Stage
Interventions: Procedure: Wide Local Excision = 1cm Margin;   Procedure: Wide Local Excision = 2cm Margin
18 Completed Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
19 Terminated Temodar and Sutent as Therapy for Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Temozolomide and SU11248
20 Completed Clinical and Histological Features of Head and Neck Melanoma
Condition: Melanoma
Intervention: Other: Data collection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.